European Hematology Association Congress (EHA)

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Patients with myeloma who received bortezomib, thalidomide, and dexamethasone with autologous stem cell transplant had better response duration when daratumumab was used as maintenance therapy.

Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel significantly improved outcomes for patients with relapsed or refractory multiple myeloma when compared with conventional therapies.

Data from EHA 2021 showed that zanubrutinib was associated with better outcomes over ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Data from the OPTIMUM/MUKNINE trial presented at 2021 EHA Congress show promise for daratumumab plus CVRd as induction in patients with multiple myeloma and certain high-risk disease factors.

The standard of care cohort comprised of patients across 3 global trials acted as a comparator for treatment with cilta-cel in patients with triple-class exposed multiple myeloma.

Further investigation will determine if initial results regarding the use of anakinra as prophylaxis for orvacabtagene autoleucel in multiple myeloma is efficacious enough for use in the real-world setting.

CancerNetwork® sat down with Ola Landgren, MD, PhD, at the 2021 EHA Congress to talk about his presentation on first-line standard of care for multiple myeloma.